

Q-linea AB (publ) (OMX: QLINEA) today announces it will provide ASTar® to Italian users of the Accelerate Pheno rapid AST system

Q-linea announces that its ASTar, a system for rapid antimicrobial susceptibility testing (rAST), has been chosen to fulfill tender obligations at several Italian laboratories, following the withdrawal of the Accelerate Pheno system from the market.

Franco Pellegrini, VP Sales EMEA at Q-linea, comments:

"We are working closely with the laboratories affected by Pheno's discontinuation to ensure a smooth and immediate transition to ASTar as their new rAST solution of choice. Customers have selected ASTar for its ease of use, broad organism and antibiotic coverage, and high-throughput capabilities. In addition to these projects, we are actively evaluating further requests from current Pheno users seeking a reliable replacement for their rAST needs."

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

Q-linea AB (publ) (OMX: QLINEA) today announces it will provide ASTar® to Italian users of the Accelerate Pheno rapid AST system